BioWorld

June 2, 2004

View Archived Issues

Pozen's Second Migraine Drug, MT 100, Turned Down By FDA

Pozen Inc.'s stock plummeted Tuesday on news that it received a not-approvable letter from the FDA for its migraine drug MT 100. (BioWorld Today) Read More

$180M Stock-Swap Merger Joins Aclara With ViroLogic

Read More

SuperGen Submits First Part Of Rolling NDA For Dacogen

Read More

ARYx Raises $55M To Fund Development Of Safer Drugs

Read More

Serono Starts Phase III Trial Of Serostim In HARS Patients

Read More

Other News To Note

Read More